四川長虹(600839.SH)收到虹雲創投基金資金分配款
格隆匯10月9日丨四川長虹(600839.SH)公佈,公司於2020年9月29日收到四川虹雲新一代信息技術創業投資基金合夥企業(有限合夥)(以下簡稱“虹雲創投基金”)做出的合夥人大會第十一次會議決議,該決議同意向其各合夥人分配資金合計1.739億元。公司及控股子公司長虹美菱股份有限公司(以下簡稱“長虹美菱”)、下屬孫公司四川長虹佳華數字技術有限公司(以下簡稱“佳華數字”)於2020年9月29日收到資金分配款合計8173.30萬元。
本次資金分配預計公司合併口徑可獲得投資收益5255.15萬元,佔公司最近一期經審計歸屬於母公司股東淨利潤的86.77%。上述5255.15萬元投資收益將計入公司2020年度損益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.